Journal Articles

  1. MDMA and mephedrone: current psychobiological models of ‘Ecstasy’ and ‘m-cat’, and future human research needs.. Research and Advances in Psychiatry 4(3), 1-6.
  2. & Substance usage intention does not affect attentional bias: implications from Ecstasy/MDMA users and alcohol drinkers. Addictive Behaviors 88, 175-181.
  3. Mood Fluctuation and Psychobiological Instability: The Same Core Functions Are Disrupted by Novel Psychoactive Substances and Established Recreational Drugs. Brain Sciences 8(3), 43
  4. & Cannabis: An Overview of its Adverse Acute and Chronic Effects and its Implications. Current Drug Abuse Reviews 10(1), 6-18.
  5. & Recreational 3,4-methylenedioxymethamphetamine or ‘ecstasy’: Current perspective and future research prospects. Journal of Psychopharmacology 31(8), 959-966.
  6. & Psychoactive drug influences on hair cortisol. Psychoneuroendocrinology 81, 159
  7. & MDMA and brain activity during neurocognitive performance: An overview of neuroimaging studies with abstinent ‘Ecstasy’ users. Neuroscience & Biobehavioral Reviews
  8. & Psychomotor Tremor and Proprioceptive Control Problems in Current and Former Stimulant Drug Users: An Accelerometer Study of Heavy Users of Amphetamine, MDMA, and Other Recreational Stimulants. The Journal of Clinical Pharmacology 57(10), 1330-1337.
  9. & Recreational stimulants, herbal, and spice cannabis: The core psychobiological processes that underlie their damaging effects. Human Psychopharmacology: Clinical and Experimental 32(3), e2594
  10. & Mephedrone and 3,4-methylenedioxy-methamphetamine: Comparative psychobiological effects as reported by recreational polydrug users. Journal of Psychopharmacology 30(12), 1313-1320.
  11. Oxytocin, cortisol and 3,4-methylenedioxymethamphetamine. Behavioural Pharmacology 27(8), 649-658.
  12. & Alcohol: drink less and live more.. Journal of Alcoholism, Drug Abuse & Substance Dependence. 2, 004-005.
  13. & Motor delays in MDMA (ecstasy) exposed infants persist to 2years. Neurotoxicology and Teratology 54, 22-28.
  14. & Mood and Psychomotor Tremor Changes following Acute Caffeine Consumption in Moderate and Minimal Caffeine Consumers. Journal of Caffeine Research 5(1), 42-49.
  15. & Novel psychoactive substances: second and third international conferences. Human Psychopharmacology: Clinical and Experimental 30(4), 209-212.
  16. Why all stimulant drugs are damaging to recreational users: an empirical overview and psychobiological explanation. Human Psychopharmacology 30, 213-224.
  17. The Psychobiological Problems of Continued Nicotine Dependency in E-Cigarette ‘Vapers’. Commentary: “Electronic Cigarettes”. Frontiers in Psychiatry 6
  18. & Developmental outcomes of 3,4-methylenedioxymethamphetamine (ecstasy)-exposed infants in the UK. Human Psychopharmacology: Clinical and Experimental 30(4), 290-294.
  19. & Greater sexual risk-taking in female and male recreational MDMA/ecstasy users compared with alcohol drinkers: a questionnaire study. Human Psychopharmacology: Clinical and Experimental 30(4), 272-275.
  20. & Reduced memory skills and increased hair cortisol levels in recent Ecstasy/MDMA users: significant but independent neurocognitive and neurohormonal deficits. Human Psychopharmacology: Clinical and Experimental 30(3), 199-207.
  21. & MDMA, cortisol, and heightened stress in recreational ecstasy users. Behavioural Pharmacology, 1
  22. Addiction: Not just brain malfunction. Nature 507(7490), 40-40.
  23. & Increased cortisol levels in hair of recent Ecstasy/MDMA users. European Neuropsychopharmacology 24(3), 369-374.
  24. MDMA is certainly damaging after 25 years of empirical research: a reply and refutation of Doblinet al. (2014). Human Psychopharmacology: Clinical and Experimental 29(2), 109-119.
  25. & MDMA and heightened cortisol: a neurohormonal perspective on the pregnancy outcomes of mothers used ‘Ecstasy’ during pregnancy. Human Psychopharmacology: Clinical and Experimental 29(1), 1-7.
  26. The Potential Dangers of Using MDMA for Psychotherapy. Journal of Psychoactive Drugs 46(1), 37-43.
  27. & Psychiatric profiles of mothers who take Ecstasy/MDMA during pregnancy: Reduced depression 1 year after giving birth and quitting Ecstasy. Journal of Psychopharmacology 28(1), 55-61.
  28. & Wild state secrets: ultra-sensitive measurement of micro-movement can reveal internal processes in animals. Frontiers in Ecology and the Environment 12(10), 582-587.
  29. et. al. Second International Conference on Novel Psychoactive Substances (NPSs): keynote addresses and conference abstracts.. Open Addiction Journal, 255-256.
  30. & Saturday night fever in ecstasy/MDMA dance clubbers: Heightened body temperature and associated psychobiological changes. Temperature 1(3), 214-219.
  31. & Novel psychoactive substances: first international conference. Human Psychopharmacology: Clinical and Experimental 28(4), 287-288.
  32. Human psychobiology of MDMA or ‘Ecstasy’: an overview of 25 years of empirical research. Human Psychopharmacology: Clinical and Experimental 28(4), 289-307.
  33. MDMA, serotonergic neurotoxicity, and the diverse functional deficits of recreational ‘Ecstasy’ users. Neuroscience & Biobehavioral Reviews 37(8), 1466-1484.
  34. & MDMA can increase cortisol levels by 800% in dance clubbers. Journal of Psychopharmacology 27(1), 113-114.
  35. & One-Year Outcomes of Prenatal Exposure to MDMA and Other Recreational Drugs. PEDIATRICS 130(3), 407-413.
  36. & Neurobehavioral outcomes of infants exposed to MDMA (Ecstasy) and other recreational drugs during pregnancy. Neurotoxicology and Teratology 34(3), 303-310.
  37. & Adult attention deficit hyperactivity disorder and other psychiatric symptoms in recreational polydrug users. Human Psychopharmacology: Clinical and Experimental 27(2), 209-216.
  38. MDMA and temperature: A review of the thermal effects of ‘Ecstasy’ in humans. Drug and Alcohol Dependence 121(1-2), 1-9.
  39. MDMA and 5-HT neurotoxicity: the empirical evidence for its adverse effects in humans - no need for translation. British Journal of Pharmacology 166(5), 1518-1520.
  40. & Applied human psychopharmacology: the practical psychobiological consequences of some novel and ancient psychoactive drugs. Human Psychopharmacology: Clinical and Experimental 27(2), 103-105.
  41. Explaining the stress-inducing effects of nicotine to cigarette smokers. Human Psychopharmacology: Clinical and Experimental 27(2), 150-155.
  42. & Event related potential (ERP) evidence for selective impairment of verbal recollection in abstinent recreational methylenedioxymethamphetamine (“Ecstasy”)/polydrug users. Psychopharmacology 216(4), 545-556.
  43. & MDMA and methamphetamine: some paradoxical negative and positive mood changes in an acute dose laboratory study. Psychopharmacology 215(3), 527-536.
  44. & Procedural and declarative memory task performance, and the memory consolidation function of sleep, in recent and abstinent ecstasy/MDMA users. Journal of Psychopharmacology 25(4), 465-477.
  45. & Hair MDMA Samples Are Consistent with Reported Ecstasy Use: Findings from a Study Investigating Effects of Ecstasy on Mood and Memory. Neuropsychobiology 63(1), 15-21.
  46. Cocaine vs Ecstasy/MDMA: Comparative Effects on Mood and Cognition in Recreational Users. The Open Addiction Journal 4(1), 36-37.
  48. & During pregnancy, recreational drug-using women stop taking ecstasy (3,4-methylenedioxy-N-methylamphetamine) and reduce alcohol consumption, but continue to smoke tobacco and cannabis: initial findings from the Development and Infancy Study. Journal of Psychopharmacology 24(9), 1403-1410.
  49. & A short self-report measure of executive function suitable for administration via the Internet.. Behavioural Research Methods & Instrumentation. 42, 709-714.
  50. & Cannabis and Ecstasy/MDMA: empirical measures of creativity in recreational users.. Journal of Psychoactive Drugs 41, 323-329.
  51. & Cannabis and Ecstasy/MDMA: empirical measures of creativity in recreational users.. Journal of Psychoactive Drugs 41, 323-329.
  52. Preface: the psychobiology of MDMA. Neuropsychobiology 60(3-4), 117-118.
  53. & The Variety of Ecstasy/MDMA Users: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. American Journal on Addictions 18(6), 452-461.
  54. & Attributions for psychobiological changes in ecstasy/MDMA and other polydrug users. Journal of Psychopharmacology 23(7), 745-758.
  55. & The high prevalence of substance use disorders among recent MDMA users compared with other drug users: Implications for intervention. Addictive Behaviors 34(8), 654-661.
  56. Cortisol and MDMA (3,4-methylenedioxymethamphetamine): neurohormonal aspects of bioenergetic stress in Ecstasy users.. Neuropsychobiology 60, 148-158.
  57. & The effects of cigarette smoking and abstinence on auditory verbal learning. Human Psychopharmacology: Clinical and Experimental 23(7), 621-627.
  58. & Dance Clubbing on MDMA and during Abstinence from Ecstasy/MDMA: Prospective Neuroendocrine and Psychobiological Changes. Neuropsychobiology 57(4), 165-180.
  59. Drug taking - for better or for worse?. The Psychologist 21, 924-927.
  60. & Sleep, energy, and self rated cognition across 7 nights following recreational ecstasy/MDMA use.. Sleep and Hypnosis 10, 16-28.

Book Chapters

  1. Clinical and medical management of conditions caused by MDMA or 'Ecstasy'. In Handbook of novel psychoactive substances. (pp. 266-290). New York and London: Routledge.
  2. MDMA assisted psychotherapy - a psychobiological analysis and critique.. In Routledge International Handbook of Psychobiology.. (pp. 10London: Routledge.

Other Research Outputs

  1. & (2017). Novel psychoactive substances: Shedding new lights on the ever-changing drug scenario and the associated health risks. (Human Psychopharmacology: Clinical and Experimental No. 32).